Omid S. Alavijeh
@oalavijeh.bsky.social
Currently:
Honorary Consultant Nephrologist and Lecturer in Renal Medicine @ UCL
Recent:
MRC Doctoral and AstraZeneca/MRC fellow
Academic kidney doctor #bioinformatics #genomics #popgen
Profile: https://profiles.ucl.ac.uk/60145-omid-sadeghialavijeh
Honorary Consultant Nephrologist and Lecturer in Renal Medicine @ UCL
Recent:
MRC Doctoral and AstraZeneca/MRC fellow
Academic kidney doctor #bioinformatics #genomics #popgen
Profile: https://profiles.ucl.ac.uk/60145-omid-sadeghialavijeh
Reposted by Omid S. Alavijeh
OK thread of all simulpubs at this year's #KidneyWk
ORIGIN-3: Atacicept pubmed.ncbi.nlm.nih.gov/41196369/
CKD as a curable dz? www.kidney-international.org/article/S008...
Albuminuria as a surrogate endpoint www.nature.com/articles/s41...
ORIGIN-3: Atacicept pubmed.ncbi.nlm.nih.gov/41196369/
CKD as a curable dz? www.kidney-international.org/article/S008...
Albuminuria as a surrogate endpoint www.nature.com/articles/s41...
November 9, 2025 at 11:30 PM
OK thread of all simulpubs at this year's #KidneyWk
ORIGIN-3: Atacicept pubmed.ncbi.nlm.nih.gov/41196369/
CKD as a curable dz? www.kidney-international.org/article/S008...
Albuminuria as a surrogate endpoint www.nature.com/articles/s41...
ORIGIN-3: Atacicept pubmed.ncbi.nlm.nih.gov/41196369/
CKD as a curable dz? www.kidney-international.org/article/S008...
Albuminuria as a surrogate endpoint www.nature.com/articles/s41...
Reposted by Omid S. Alavijeh
⏩ Next #NephJC is on IgA nephropathy @kdigo.org guideline
🎨 Nice visual summary by @roxnonna23.bsky.social
www.nephjc.com/news/2025/10...
🎨 Nice visual summary by @roxnonna23.bsky.social
www.nephjc.com/news/2025/10...
KDIGO 2025 IgA guidelines - Visual Abstract — NephJC
KDIGO 2025 is here. IgAN management is evolving with precision risk tools, new therapies, and a stronger focus on kidney protection. Check out the visual abstract created by Natalia Nombera
www.nephjc.com
October 27, 2025 at 5:27 PM
⏩ Next #NephJC is on IgA nephropathy @kdigo.org guideline
🎨 Nice visual summary by @roxnonna23.bsky.social
www.nephjc.com/news/2025/10...
🎨 Nice visual summary by @roxnonna23.bsky.social
www.nephjc.com/news/2025/10...
Reposted by Omid S. Alavijeh
Obinituzumab aka ‘Obi’ is now FDA approved for lupus nephritis
finance.yahoo.com/news/fda-app...
#lupus
finance.yahoo.com/news/fda-app...
#lupus
FDA Approves Genentech’s Gazyva for the Treatment of Lupus Nephritis
SOUTH SAN FRANCISCO, Calif., October 20, 2025--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Gazyva...
finance.yahoo.com
October 20, 2025 at 11:14 AM
Obinituzumab aka ‘Obi’ is now FDA approved for lupus nephritis
finance.yahoo.com/news/fda-app...
#lupus
finance.yahoo.com/news/fda-app...
#lupus
Reposted by Omid S. Alavijeh
In a new "Mechanisms of Kidney Disease" article in #ASNJASN, authors explore population studies and the genetic architecture of kidney diseases, highlighting a spectrum of risk. Read more: kidney.pub/JASN0893
@dannygale.bsky.social
@dannygale.bsky.social
October 13, 2025 at 8:00 PM
In a new "Mechanisms of Kidney Disease" article in #ASNJASN, authors explore population studies and the genetic architecture of kidney diseases, highlighting a spectrum of risk. Read more: kidney.pub/JASN0893
@dannygale.bsky.social
@dannygale.bsky.social
Reposted by Omid S. Alavijeh
If you’re interested in learning about all things genetic in nephrology, come to our Renal Genomics course in London, 5-6 March 2026!
We are proud to be organising the inaugural UCL Renal Genomics Course 5-6 March 2026! (London + Online). Practical genomics for the clinic: test choice, VUS, counselling & real cases across all aspects of rare renal disease.
Book 👉 ucl.ac.uk/short-course...
#Genomics #rarerenal #nephsky
Book 👉 ucl.ac.uk/short-course...
#Genomics #rarerenal #nephsky
Renal Genomics Course
A two-day course providing a practical, clinically‑focused update on the principles and practice of genomic medicine in kidney disease.
ucl.ac.uk
October 2, 2025 at 2:55 PM
If you’re interested in learning about all things genetic in nephrology, come to our Renal Genomics course in London, 5-6 March 2026!
This will be fantastic (not just because I am helping to organise it)! An amazing line up of speakers and topics. Hope to see you there!
We are proud to be organising the inaugural UCL Renal Genomics Course 5-6 March 2026! (London + Online). Practical genomics for the clinic: test choice, VUS, counselling & real cases across all aspects of rare renal disease.
Book 👉 ucl.ac.uk/short-course...
#Genomics #rarerenal #nephsky
Book 👉 ucl.ac.uk/short-course...
#Genomics #rarerenal #nephsky
Renal Genomics Course
A two-day course providing a practical, clinically‑focused update on the principles and practice of genomic medicine in kidney disease.
ucl.ac.uk
September 28, 2025 at 10:20 PM
This will be fantastic (not just because I am helping to organise it)! An amazing line up of speakers and topics. Hope to see you there!
🚨 New paper alert 🚨
Proud to share our work in AJKD: “Quantifying APOL1, HLA, and other genetic contributions to unexplained kidney failure”
What drives kidney failure when the cause is unknown? 🧵
www.ajkd.org/article/S027...
Proud to share our work in AJKD: “Quantifying APOL1, HLA, and other genetic contributions to unexplained kidney failure”
What drives kidney failure when the cause is unknown? 🧵
www.ajkd.org/article/S027...
Quantifying APOL1, Human Leukocyte Antigen, and Other Genetic Contributions to Unexplained Kidney Failure
Unexplained kidney failure (uKF) affects 15% of individuals needing kidney replacement
therapy. The lack of a clear diagnosis creates uncertainty about recurrence, familial
risk, and trial eligibility...
www.ajkd.org
September 28, 2025 at 9:58 PM
🚨 New paper alert 🚨
Proud to share our work in AJKD: “Quantifying APOL1, HLA, and other genetic contributions to unexplained kidney failure”
What drives kidney failure when the cause is unknown? 🧵
www.ajkd.org/article/S027...
Proud to share our work in AJKD: “Quantifying APOL1, HLA, and other genetic contributions to unexplained kidney failure”
What drives kidney failure when the cause is unknown? 🧵
www.ajkd.org/article/S027...
Reposted by Omid S. Alavijeh
🫀 #Hypertension in autosomal dominant polycystic kidney disease: unique pathways, common consequences.
In #ADPKD, high blood pressure is often the first clinical sign and not just a complication of the kidney disease.
Actually its mechanisms differ markedly from other CKD-related hypertension... 🧵
In #ADPKD, high blood pressure is often the first clinical sign and not just a complication of the kidney disease.
Actually its mechanisms differ markedly from other CKD-related hypertension... 🧵
August 6, 2025 at 10:05 AM
🫀 #Hypertension in autosomal dominant polycystic kidney disease: unique pathways, common consequences.
In #ADPKD, high blood pressure is often the first clinical sign and not just a complication of the kidney disease.
Actually its mechanisms differ markedly from other CKD-related hypertension... 🧵
In #ADPKD, high blood pressure is often the first clinical sign and not just a complication of the kidney disease.
Actually its mechanisms differ markedly from other CKD-related hypertension... 🧵
Reposted by Omid S. Alavijeh
A paper in Nature reports whole-genome sequences for 490,640 participants from the UK Biobank and combines these data with phenotypic data to provide new insights into the relationship between human variation and sequence variation. go.nature.com/415CMhr 🧬 🧪
August 24, 2025 at 1:54 AM
A paper in Nature reports whole-genome sequences for 490,640 participants from the UK Biobank and combines these data with phenotypic data to provide new insights into the relationship between human variation and sequence variation. go.nature.com/415CMhr 🧬 🧪
Last week I was taking someone through the basics of human GWAS - that the fundamental model is simple (sooo simple!) but the complications are (a) population stratification and (b) multiple testing.
July 28, 2025 at 1:58 PM
Reposted by Omid S. Alavijeh
📣 Latest from the lab: Performance of deep-learning-based approaches to improve polygenic scores www.nature.com/articles/s41...
Its thought deep learning will substantially improve PGS but the reality is MANY have tried but no/little gain has been seen so far. Here we report our negative results.
Its thought deep learning will substantially improve PGS but the reality is MANY have tried but no/little gain has been seen so far. Here we report our negative results.
June 5, 2025 at 1:37 PM
📣 Latest from the lab: Performance of deep-learning-based approaches to improve polygenic scores www.nature.com/articles/s41...
Its thought deep learning will substantially improve PGS but the reality is MANY have tried but no/little gain has been seen so far. Here we report our negative results.
Its thought deep learning will substantially improve PGS but the reality is MANY have tried but no/little gain has been seen so far. Here we report our negative results.
📘 What could nephrology look like in 2050?
This article for the Future Healthcare Journal was fun to write! — here’s a 🧵 of what might be coming next in kidney care:
shorturl.at/A18zK
This article for the Future Healthcare Journal was fun to write! — here’s a 🧵 of what might be coming next in kidney care:
shorturl.at/A18zK
The future of nephrology in 2050
As medicine advances at an unprecedented pace, the field of nephrology is poised for transformative change. By 2050, breakthroughs in kidney disease p…
shorturl.at
April 2, 2025 at 1:43 PM
📘 What could nephrology look like in 2050?
This article for the Future Healthcare Journal was fun to write! — here’s a 🧵 of what might be coming next in kidney care:
shorturl.at/A18zK
This article for the Future Healthcare Journal was fun to write! — here’s a 🧵 of what might be coming next in kidney care:
shorturl.at/A18zK